中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HBV感染免疫耐受期患者应进行抗病毒治疗降低病毒量

林炳亮

引用本文:
Citation:

HBV感染免疫耐受期患者应进行抗病毒治疗降低病毒量

DOI: 10.3969/j.issn.1001-5256.2021.04.009
详细信息
    作者简介:

    林炳亮(1968—),男,医学博士,科副主任,主要从事病毒性肝炎防治、终末期肝病救治方面的研究

  • 中图分类号: R512.62

Patients in the immune-tolerant phase of hepatitis B virus infection should receive antiviral therapy to reduce viral load

  • [1] Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
    [3] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [4] TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    [5] NGUYEN MH, GARCIA RT, TRINH HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels[J]. Am J Gastroenterol, 2009, 104(9): 2206-2213. DOI: 10.1038/ajg.2009.248.
    [6] CHEN J, XU CR, XI M, et al. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels[J]. J Viral Hepat, 2017, 24(7): 573-579. DOI: 10.1111/jvh.12679.
    [7] MILICH DR, JONES JE, HUGHES JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?[J]. Proc Natl Acad Sci U S A, 1990, 87(17): 6599-6603. DOI: 10.1073/pnas.87.17.6599.
    [8] TIAN Y, KUO CF, AKBARI O, et al. Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission[J]. Immunity, 2016, 44(5): 1204-1214. DOI: 10.1016/j.immuni.2016.04.008.
    [9] HONG M, SANDALOVA E, LOW D, et al. Trained immunity in newborn infants of HBV-infected mothers[J]. Nat Commun, 2015, 6: 6588. DOI: 10.1038/ncomms7588.
    [10] VANWOLLEGHEM T, HOU J, VAN OORD G, et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells[J]. Hepatology, 2015, 62(1): 87-100. DOI: 10.1002/hep.27805.
    [11] BERTOLETTI A, FERRARI C. Adaptive immunity in HBV infection[J]. J Hepatol, 2016, 64(1 Suppl): s71-s83. DOI: 10.1016/j.jhep.2016.01.026.
    [12] KENNEDY P, SANDALOVA E, JO J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B[J]. Gastroenterology, 2012, 143(3): 637-645. DOI: 10.1053/j.gastro.2012.06.009.
    [13] PARK JJ, WONG DK, WAHED AS, et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B[J]. Gastroenterology, 2016, 150(3): 684-695.e5. DOI: 10.1053/j.gastro.2015.11.050.
    [14] CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
    [15] LIAW YF, SUNG JJ, CHOW WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15): 1521-1531. DOI: 10.1056/NEJMoa033364.
    [16] CHANG Y, CHOE WH, SINN DH, et al. Nucleos(t)ide analogue treatment for adult patients with HBeAg-positive chronic infection with genotype C hepatitis B virus: A nationwide real-life study[J]. J Infect Dis, 2017, 26(11): 1407-1414. DOI: 10.1093/infdis/jix506.
    [17] PARK JY, PARK YN, KIM DY, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels[J]. J Viral Hepat, 2008, 15(8): 615-621. DOI: 10.1111/j.1365-2893.2008.00989.x.
    [18] MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998.e4. DOI: 10.1053/j.gastro.2016.07.012.
    [19] BILL CA, SUMMERS J. Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration[J]. Proc Natl Acad Sci U S A, 2004, 101(30): 11135-11140. DOI: 10.1073/pnas.0403925101.
    [20] KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
    [21] LEE HW, KIM SU, OIDOV B, et al. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs those with virological response by antivirals[J]. Sci Rep, 2019, 9(1): 2508. DOI: 10.1038/s41598-019-39043-2.
  • 加载中
计量
  • 文章访问数:  252
  • HTML全文浏览量:  115
  • PDF下载量:  68
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-20
  • 录用日期:  2021-02-28
  • 出版日期:  2021-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回